FAKTOR OPTIONSSCHEIN - GENMAB | Market Closed - Deutsche Boerse AG 10:21:03 2024-06-07 am EDT | ||
| 3.61 EUR | +4.94% |
|
| Current month | +4.64% | ||
| 1 month | +14.97% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 3.61 | +4.94% |
| 24-06-06 | 3.44 | 0.00% |
| 24-06-04 | 3.44 | +3.93% |
| 24-06-03 | 3.31 | -4.06% |
| 24-05-31 | 3.45 | -2.54% |
Delayed Quote Deutsche Boerse AG
Last update June 07, 2024 at 10:21 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
BNP Paribas
|
| WKN | PD4GMS |
| ISIN | DE000PD4GMS3 |
| Date issued | 2021-11-18 |
| Strike | 1,940 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.39 € |
|---|---|
| Lowest since issue | 1.31 € |
| Spread | 0.02 € |
| Spread % | 0.57% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
1,930
DKK
Average target price
2,464
DKK
Spread / Average Target
+27.67%
- Stock Market
- Certificates
- Certificat
